- Home
- HEQ vs CGEN Comparison
HEQ vs CGEN Comparison
Compare HEQ & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEQ
- CGEN
- Stock Information
- Founded
- HEQ 2011
- CGEN 1993
- Country
- HEQ United States
- CGEN Israel
- Employees
- HEQ N/A
- CGEN N/A
- Industry
- HEQ Investment Managers
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HEQ Finance
- CGEN Health Care
- Exchange
- HEQ Nasdaq
- CGEN Nasdaq
- Market Cap
- HEQ 128.4M
- CGEN 125.3M
- IPO Year
- HEQ N/A
- CGEN 2000
- Fundamental
- Price
- HEQ $10.66
- CGEN $1.62
- Analyst Decision
- HEQ
- CGEN
- Analyst Count
- HEQ 0
- CGEN 0
- Target Price
- HEQ N/A
- CGEN N/A
- AVG Volume (30 Days)
- HEQ 43.1K
- CGEN 522.7K
- Earning Date
- HEQ 01-01-0001
- CGEN 11-10-2025
- Dividend Yield
- HEQ 9.78%
- CGEN N/A
- EPS Growth
- HEQ N/A
- CGEN N/A
- EPS
- HEQ N/A
- CGEN N/A
- Revenue
- HEQ N/A
- CGEN $22,144,000.00
- Revenue This Year
- HEQ N/A
- CGEN N/A
- Revenue Next Year
- HEQ N/A
- CGEN $208.08
- P/E Ratio
- HEQ N/A
- CGEN N/A
- Revenue Growth
- HEQ N/A
- CGEN N/A
- 52 Week Low
- HEQ $9.08
- CGEN $1.13
- 52 Week High
- HEQ $11.84
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- HEQ 47.17
- CGEN 44.43
- Support Level
- HEQ $10.58
- CGEN $1.61
- Resistance Level
- HEQ $10.79
- CGEN $1.80
- Average True Range (ATR)
- HEQ 0.11
- CGEN 0.11
- MACD
- HEQ -0.01
- CGEN -0.03
- Stochastic Oscillator
- HEQ 24.14
- CGEN 19.35
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.